Categories: Material Information

GLAXO responds to drug court Rawalpindi judgment

In a notification sent to PSX on 24/04/2024, GlaxoSmithKline Pakistan Limited (GLAXO) has announced its legal position on the GLAXO drug case judgment.

We would like to inform you that the Drug Court Rawalpindi has passed judgement dated April 22, 2024, in Case Judicial No. 4229/DC/Rwp/22 against the current and former officers of GSK under the Drugs Act 1976 related to the provision of sub-standard drugs.

GSK as well as the officers impleaded in the proceedings hereby deny any sort of wrong doing in the matter and are taking immediate steps to challenge the aforementioned judgment before the appellate forum. We would also like to inform you that GSK will keep all stakeholders abreast of any significant updates in this regard.

The shares of GLAXO were last trading at Rs. 98.89 today.

Aamir Hayat

Recent Posts

AGP Healthcare for a Better Tomorrow

AGP Limited (AGP) monthly market structure is showing strong bullish trend. Even this stock broke…

5 days ago

Why dividends cause share price drop if they’re paid from earnings?

When a dividend is paid, the share price drops by approximately the same amount because…

2 weeks ago

MUGHAL right shares – 3 things to know before subscribing

On November 5, 2024, Mughal Iron & Steel Industries Limited (MUGHAL) announced a unique rights…

4 weeks ago

How to analyze pharmaceutical sector

How to analyze pharma sector companies in PSX. Pakistan's pharma sector is considered a complicated…

1 month ago

Shifa International (SHFA) has returned 150% in two months, will the rally continue?

Shifa International (SHFA) has already rallied 150%, but there is still more upside to the…

2 months ago

How is HMB handling financial challenges to grow?

Habib Metropolitan Bank Limited (HMB) recently released its second-quarter results for 2024, revealing a mixed…

3 months ago